Skip to main content
OpenTrials

Clinical trial condition

Hematologic Diseases

Explore clinical trials studying Hematologic Diseases. Study availability and eligibility vary by location and protocol.

15,467 public trials 2,848 recruiting studies
Refine in advanced search Browse all conditions

Hematologic Diseases trial results

Active, not recruiting

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

NCT01169337

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Anchorage Oncology Centre Anchorage, Alaska, United States
  • Katmai Oncology Group Anchorage, Alaska, United States
View all 605 locations
View Trial Details
Active, not recruiting

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

NCT04623541

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +17 more
Locations
  • O'Neal Comprehensive Cancer Center at University of Alabama at Birmingham Birmingham, Alabama, United States
  • University of California Davis Medical Center Sacramento California City, California, United States
  • City of Hope National Medical Center Duarte, California, United States
  • Cedars-Sinai Medical Center Los Angeles, California, United States
View all 81 locations
View Trial Details
Active, not recruiting

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)

NCT04542824

Conditions
Chronic Disease, Diffuse Large B Cell Lymphoma, Disease Attributes, +25 more
Locations
  • Tohoku University Hoaspital Sendai, Miyagi, Japan
  • Aichi Cancer Center Hospital Aichi, Japan
  • NHO Nagoya Medical Center Aichi, Japan
  • National Cancer Center Hospital East Chiba, Japan
View all 15 locations
View Trial Details
Active, not recruiting

PICAROS - Acalabrutinib RWE on 1L CLL in Spain

NCT05999877

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations
  • Research Site Almería, Andalusia, Spain
  • Research Site Córdoba, Andalusia, Spain
  • Research Site Granada, Andalusia, Spain
  • Research Site Jaén, Andalusia, Spain
View all 47 locations
View Trial Details
Active, not recruiting

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

NCT03625037

Conditions
Aggressive B-cell Non-Hodgkin Lymphoma (aNHL), Chronic Disease, DLBCL, +26 more
Locations
  • Arizona Mayo Clinic Phoenix, Arizona, United States
  • University of California at San Francisco San Francisco, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
View all 85 locations
View Trial Details
Active, not recruiting

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

NCT02003222

Conditions
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Burkitt Lymphoma, +20 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
View all 544 locations
View Trial Details
Active, not recruiting

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

NCT02143414

Conditions
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, +23 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
  • University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
  • John L McClellan Memorial Veterans Hospital Little Rock, Arkansas, United States
View all 195 locations
View Trial Details
Active, not recruiting

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

NCT04284787

Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, +8 more
Locations
  • Smilow Cancer Hospital Care Center at Greenwich Greenwich, Connecticut, United States
  • Smilow Cancer Hospital Care Center at Saint Francis Hartford, Connecticut, United States
  • Yale University New Haven, Connecticut, United States
  • MedStar Georgetown University Hospital Washington D.C., District of Columbia, United States
View all 29 locations
View Trial Details

Related conditions